Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation.
In this study, several factors influencing the occurrence of active CMV infection after organ transplantation (Tx) are analysed. For this purpose, 105 heart, kidney and lung transplant recipients who were CMV-positive or had a CMV-positive donor, were closely monitored for active CMV infection by antigenaemia, cultures, CMV serology and lymphocyte proliferation (LP) to CMV. Univariate and multivariate regression analysis were performed. As pretransplant risk factors the HLA-type and numbers of HLA mismatches between recipients and their donors, and the CMV serology of the recipient and donor were analysed. A new finding was that recipients of donors positive for HLA-B7 were especially at risk for developing active CMV infection (P = 0.03) and CMV disease (P = 0.03). This was not due to increased rejection treatment in these patients. Post-transplant risk factors for development of active CMV infection were absence of detectable cellular immunity to CMV (lymphocyte proliferation) after Tx (P < 0.01) and rejection treatment with OKT3 or ATG (P = 0.05). High levels of IgG anti-CMV did not prevent occurrence of active CMV infection or CMV disease in the CMV+ recipients.
Boland
G J
GJ
Department of Immuno-Haematology, University Hospital Utrecht, The Netherlands.
Hene
R J
RJ
Ververs
C
C
de Haan
M A
MA
de Gast
G C
GC
D000914:Antibodies, Viral / Q000097:blood; D000961:Antilymphocyte Serum / Q000009:adverse effects; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000276:immunology; D005260:Female; D006084:Graft Rejection; D006680:HLA Antigens; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008213:Lymphocyte Activation; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects; D016377:Organ Transplantation / Q000009:adverse effects*; D012307:Risk Factors; D014019:Tissue Donors
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3